Upstart Weight-Loss Drug Maker Jumps 75% on Strong Test Results

Structure Therapeutics Inc. jumped to a record high Friday after new data on its oral weight-loss drug fueled expectations that the San Francisco-based company is closing the gap with larger competitors such as Pfizer Inc.

Results from an early-stage trial of Structure’s small molecule GLP-1 drug, dubbed GSBR-1290, were “firmly positive,” BMO Capital Markets analyst Evan David Seigerman said in a note. After four weeks, patients with obesity lost about 4.9% of their weight and none of them had to discontinue taking the drug because of side effects.

The company’s shares jumped as much as 75% in New York ...